\begin{longtable}{p{0.2\textwidth}p{0.2\textwidth}p{0.2\textwidth}p{0.2\textwidth}p{0.2\textwidth}}
   & T2D & Obesity & Unknown & Overall \\ 
  \hline 
\endfirsthead 
\multicolumn{5}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & Type II Diabetes & Obesity & Unknown & Overall\\ \hline 
\endhead 
\hline \multicolumn{5}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=177235) & (N=26496) & (N=70831) & (N=274562) \\ 
  Age &  &  &  &  \\ 
    Mean (SD) & 59 (13) & 48 (12) & 54 (14) & 57 (13) \\ 
  Age Group &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 27371 (15\%) & 10530 (40\%) & 18014 (25\%) & 55915 (20\%) \\ 
    45-64 & 90339 (51\%) & 13819 (52\%) & 36003 (51\%) & 140161 (51\%) \\ 
    65+ & 59525 (34\%) & 2147 (8\%) & 16814 (24\%) & 78486 (29\%) \\ 
  Sex &  &  &  &  \\ 
    Female & 104675 (59\%) & 21958 (83\%) & 48546 (69\%) & 175179 (64\%) \\ 
    Male & 72344 (41\%) & 4530 (17\%) & 22198 (31\%) & 99072 (36\%) \\ 
    Unknown & 216 (0\%) & 8 (0\%) & 87 (0\%) & 311 (0\%) \\ 
  Race &  &  &  &  \\ 
    White & 124561 (70\%) & 19022 (72\%) & 51612 (73\%) & 195195 (71\%) \\ 
    Black & 29186 (16\%) & 4839 (18\%) & 10729 (15\%) & 44754 (16\%) \\ 
    Asian & 5060 (3\%) & 315 (1\%) & 1686 (2\%) & 7061 (3\%) \\ 
    AI or AN & 1208 (1\%) & 131 (0\%) & 637 (1\%) & 1976 (1\%) \\ 
    NH or PI & 722 (0\%) & 69 (0\%) & 373 (1\%) & 1164 (0\%) \\ 
    Other Race & 9886 (6\%) & 1289 (5\%) & 3636 (5\%) & 14811 (5\%) \\ 
    Declined to answer & 1712 (1\%) & 254 (1\%) & 477 (1\%) & 2443 (1\%) \\ 
    Unknown & 4900 (3\%) & 577 (2\%) & 1681 (2\%) & 7158 (3\%) \\ 
  Ethnicity &  &  &  &  \\ 
    Hispanic or Latino & 19132 (11\%) & 2564 (10\%) & 6779 (10\%) & 28475 (10\%) \\ 
    Not Hispanic or Latino & 147324 (83\%) & 22738 (86\%) & 60455 (85\%) & 230517 (84\%) \\ 
    Declined to answer & 2205 (1\%) & 326 (1\%) & 674 (1\%) & 3205 (1\%) \\ 
    Unknown & 8574 (5\%) & 868 (3\%) & 2923 (4\%) & 12365 (5\%) \\ 
  T2D & 137762 (78\%) & 2081 (8\%) & 42017 (59\%) & 181860 (66\%) \\ 
  Obesity or Overweight & 139572 (79\%) & 24918 (94\%) & 65225 (92\%) & 229715 (84\%) \\ 
  Generic &  &  &  &  \\ 
    Semaglutide & 74586 (42\%) & 18781 (71\%) & 47908 (68\%) & 141275 (51\%) \\ 
    Dulaglutide & 68330 (39\%) & 0 (0\%) & 0 (0\%) & 68330 (25\%) \\ 
    Liraglutide & 10300 (6\%) & 7715 (29\%) & 22921 (32\%) & 40936 (15\%) \\ 
    Tirzepatide & 14118 (8\%) & 0 (0\%) & 2 (0\%) & 14120 (5\%) \\ 
    Exenatide & 7705 (4\%) & 0 (0\%) & 0 (0\%) & 7705 (3\%) \\ 
    Lixisenatide & 2196 (1\%) & 0 (0\%) & 0 (0\%) & 2196 (1\%) \\ 
  Brand &  &  &  &  \\ 
    Ozempic & 54114 (31\%) & 0 (0\%) & 0 (0\%) & 54114 (20\%) \\ 
    Rybelsus & 16523 (9\%) & 0 (0\%) & 0 (0\%) & 16523 (6\%) \\ 
    Wegovy & 0 (0\%) & 18780 (71\%) & 0 (0\%) & 18780 (7\%) \\ 
    Trulicity & 68331 (39\%) & 0 (0\%) & 0 (0\%) & 68331 (25\%) \\ 
    Victoza & 10300 (6\%) & 0 (0\%) & 0 (0\%) & 10300 (4\%) \\ 
    Saxenda & 0 (0\%) & 7716 (29\%) & 0 (0\%) & 7716 (3\%) \\ 
    Mounjaro & 14118 (8\%) & 0 (0\%) & 0 (0\%) & 14118 (5\%) \\ 
    Bydureon & 3360 (2\%) & 0 (0\%) & 0 (0\%) & 3360 (1\%) \\ 
    Byetta & 348 (0\%) & 0 (0\%) & 0 (0\%) & 348 (0\%) \\ 
    Soliqua & 1612 (1\%) & 0 (0\%) & 0 (0\%) & 1612 (1\%) \\ 
    Unknown & 8529 (5\%) & 0 (0\%) & 70831 (100\%) & 79360 (29\%) \\ 
  Period &  &  &  &  \\ 
    2018 Jan-Jun & 5977 (3\%) & 145 (1\%) & 3520 (5\%) & 9642 (4\%) \\ 
    2018 Jul-Dec & 6783 (4\%) & 165 (1\%) & 3830 (5\%) & 10778 (4\%) \\ 
    2019 Jan-Jun & 8589 (5\%) & 202 (1\%) & 5080 (7\%) & 13871 (5\%) \\ 
    2019 Jul-Dec & 8002 (5\%) & 233 (1\%) & 5361 (8\%) & 13596 (5\%) \\ 
    2020 Jan-Jun & 9142 (5\%) & 467 (2\%) & 3803 (5\%) & 13412 (5\%) \\ 
    2020 Jul-Dec & 12838 (7\%) & 839 (3\%) & 3088 (4\%) & 16765 (6\%) \\ 
    2021 Jan-Jun & 18519 (10\%) & 1215 (5\%) & 4118 (6\%) & 23852 (9\%) \\ 
    2021 Jul-Dec & 19058 (11\%) & 2782 (10\%) & 5606 (8\%) & 27446 (10\%) \\ 
    2022 Jan-Jun & 22142 (12\%) & 3740 (14\%) & 8048 (11\%) & 33930 (12\%) \\ 
    2022 Jul-Dec & 29602 (17\%) & 3708 (14\%) & 11391 (16\%) & 44701 (16\%) \\ 
    2023 Jan-Jun & 36583 (21\%) & 13000 (49\%) & 16986 (24\%) & 66569 (24\%) \\ 
    2023 Jul-Dec & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
  Atrial Fibrilation & 14367 (8\%) & 739 (3\%) & 4888 (7\%) & 19994 (7\%) \\ 
  Asthma & 31008 (17\%) & 5519 (21\%) & 15294 (22\%) & 51821 (19\%) \\ 
  CKD & 29709 (17\%) & 1016 (4\%) & 10113 (14\%) & 40838 (15\%) \\ 
  COPD & 15919 (9\%) & 869 (3\%) & 5842 (8\%) & 22630 (8\%) \\ 
  Glaucoma & 4740 (3\%) & 250 (1\%) & 1738 (2\%) & 6728 (2\%) \\ 
  Heart Failure & 17742 (10\%) & 709 (3\%) & 6144 (9\%) & 24595 (9\%) \\ 
  Hyperlipidemia & 126932 (72\%) & 12318 (46\%) & 47598 (67\%) & 186848 (68\%) \\ 
  Hypertension & 128547 (73\%) & 12476 (47\%) & 48273 (68\%) & 189296 (69\%) \\ 
  Ischemic Heart Disease & 17664 (10\%) & 705 (3\%) & 5914 (8\%) & 24283 (9\%) \\ 
  Acute MI & 7365 (4\%) & 288 (1\%) & 2641 (4\%) & 10294 (4\%) \\ 
  Ischemic Stroke & 635 (0\%) & 34 (0\%) & 215 (0\%) & 884 (0\%) \\ 
  Major Depressive Disorder & 33656 (19\%) & 6316 (24\%) & 19001 (27\%) & 58973 (21\%) \\ 
  Osteoporosis & 6446 (4\%) & 562 (2\%) & 2450 (3\%) & 9458 (3\%) \\ 
  Bariatric Surgery & 3475 (2\%) & 1654 (6\%) & 2715 (4\%) & 7844 (3\%) \\ 
  Metformin & 103666 (58\%) & 2924 (11\%) & 33637 (47\%) & 140227 (51\%) \\ 
  SGLT2i & 39207 (22\%) & 252 (1\%) & 9534 (13\%) & 48993 (18\%) \\ 
  DPP4 & 30225 (17\%) & 111 (0\%) & 7626 (11\%) & 37962 (14\%) \\ 
  Sulfonylurea & 47165 (27\%) & 149 (1\%) & 13587 (19\%) & 60901 (22\%) \\ 
  Insulin & 18256 (10\%) & 649 (2\%) & 7461 (11\%) & 26366 (10\%) \\ 
  Orlistat & 173 (0\%) & 84 (0\%) & 235 (0\%) & 492 (0\%) \\ 
  Phentermine Topiramate & 491 (0\%) & 490 (2\%) & 733 (1\%) & 1714 (1\%) \\ 
  BMI &  &  &  &  \\ 
    Mean (SD) & 37 (8.4) & 39 (8.2) & 39 (8.6) & 37 (8.5) \\ 
    Missing & 87114 (49.2\%) & 14383 (54.3\%) & 24145 (34.1\%) & 125642 (45.8\%) \\ 
  Weight (in lbs) &  &  &  &  \\ 
    Mean (SD) & 230 (57) & 240 (55) & 240 (57) & 230 (57) \\ 
    Missing & 61101 (34.5\%) & 9463 (35.7\%) & 22289 (31.5\%) & 92853 (33.8\%) \\ 
  HbA1c &  &  &  &  \\ 
    Mean (SD) & 8.1 (1.9) & 5.7 (0.63) & 7.4 (2.0) & 7.8 (2.0) \\ 
    Missing & 46789 (26.4\%) & 13410 (50.6\%) & 18377 (25.9\%) & 78576 (28.6\%) \\ 
  \hline
\caption{Characteristics of patients first prescribed a GLP-1 RA, by FDA-labeled use.\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_use}
\end{longtable}
